First human use of RF ablation to treat HoCM

April 2021

Tau Medical Inc.

Tau Medical announced the first human use of TIRA, an RF ablation technology treating HoCM (Hypertrophic Obstructive Cardiomyopathy). The procedure was performed by an experienced team in PNUYH (Pusan National University Yangsan Hospital). 


HoCM is a disease in which the heart muscle becomes thickened (hypertrophied). The thickened heart muscle can make it harder for the heart to pump blood.[1]


HoCM patients usually get treatment like medications or septal myectomy (open heart surgery) or septal alcohol ablation. Tau’s TIRA catheter is delivered to the thickened septum coronary sinus percutaneously and ablate the thickened septum.

The TIRA for HoCM was approved for Early Feasibility Study by the Korean Ministry of Food and Drug Safety (MFDS).


[1] source: Mayo Clinic website



The TIRA, Transcatheter Interventional RF Ablation, is a catheter with electrode tips which delivers RF (Radio Frequency) energy to target tissue and ablates the tissue through heat. The device consists of electrode catheter and RF generator. Since the catheter can be delivered over the guide wire, it can be applied to various areas, and since it has a cooling mechanism inside the catheter, it can show enough ablation effect without charring the tissue. Tau is also testing the TIRA for HoCM (Hypertrophic Obstructive Cardiomyopathy) and peripheral lung cancer as well as VoM ablation.


[Tau Medical Inc.]

Tau Medical is developing trans-catheter devices for structural heart diseases like MR (Mitral valve regurgitation), TR (Tricuspid valve regurgitation) and HoCM (Hypertrophic Obstructive Cardiomyopathy). Tau’s Cerclage MR is well known as an innovative annuloplasty treatment for MR and enlarged LV reshaping, and is now under clinical study.



© Tau-Medical Inc. All Rights Reserved.